Effect of sampling on BACE‐1 ligands binding free energy predictions via MM‐PBSA calculations

The BACE‐1 enzyme is a prime target to find a cure to Alzheimer's disease. In this article, we used the MM‐PBSA approach to compute the binding free energies of 46 reported ligands to this enzyme. After showing that the most probable protonation state of the catalytic dyad is mono‐protonated (on ASP32), we performed a thorough analysis of the parameters influencing the sampling of the conformational space (in total, more than 35 μs of simulations were performed). We show that ten simulations of 2 ns gives better results than one of 50 ns. We also investigated the influence of the protein force field, the water model, the periodic boundary conditions artifacts (box size), as well as the ionic strength. Amber03 with TIP3P, a minimal distance of 1.0 nm between the protein and the box edges and a ionic strength of I = 0.2 M provides the optimal correlation with experiments. Overall, when using these parameters, a Pearson correlation coefficient of R = 0.84 (R2 = 0.71) is obtained for the 46 ligands, spanning eight orders of magnitude of Kd (from 0.017 nm to 2000 μM, i.e., from −14.7 to −3.7 kcal/mol), with a ligand size from 22 to 136 atoms (from 138 to 937 g/mol). After a two‐parameter fit of the binding affinities for 12 of the ligands, an error of RMSD = 1.7 kcal/mol was obtained for the remaining ligands. © 2017 Wiley Periodicals, Inc.

[1]  Eugene I Shakhnovich,et al.  OpenGrowth: An Automated and Rational Algorithm for Finding New Protein Ligands. , 2016, Journal of medicinal chemistry.

[2]  Ramesh Padmanabha,et al.  Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis. , 2012, Journal of medicinal chemistry.

[3]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[4]  Pin-Chih Su,et al.  Comparison of radii sets, entropy, QM methods, and sampling on MM‐PBSA, MM‐GBSA, and QM/MM‐GBSA ligand binding energies of F. tularensis enoyl‐ACP reductase (FabI) , 2015, J. Comput. Chem..

[5]  L. Nilsson,et al.  Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K , 2001 .

[6]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[7]  M. Parrinello,et al.  Isothermal-isobaric molecular dynamics using stochastic velocity rescaling. , 2009, The Journal of chemical physics.

[8]  W. L. Jorgensen.  Quantum and statistical mechanical studies of liquids. 10. Transferable intermolecular potential functions for water, alcohols, and ethers. Application to liquid water , 2002 .

[9]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[10]  Lin Hong,et al.  Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. , 2007, Journal of medicinal chemistry.

[11]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..

[12]  Anders Hallberg,et al.  Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core. , 2010, Bioorganic & medicinal chemistry.

[13]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[14]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997 .

[15]  H. Gohlke,et al.  Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.

[16]  Hwangseo Park,et al.  Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. , 2003, Journal of the American Chemical Society.

[17]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[18]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[19]  Carlos Vega,et al.  Simulating water with rigid non-polarizable models: a general perspective. , 2011, Physical chemistry chemical physics : PCCP.

[20]  Christian Kramer,et al.  MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement , 2013, J. Chem. Inf. Model..

[21]  Qi Zhang,et al.  Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. , 2008, Bioorganic & medicinal chemistry letters.

[22]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[23]  Jie Li,et al.  Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set , 2014, J. Chem. Inf. Model..

[24]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[25]  C. Vega,et al.  A general purpose model for the condensed phases of water: TIP4P/2005. , 2005, The Journal of chemical physics.

[26]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[27]  Lin Hong,et al.  Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design† , 2001 .

[28]  Brian McKittrick,et al.  Discovery of potent iminoheterocycle BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[29]  Tímea Polgár,et al.  Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.

[30]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[31]  Charles H. Reynolds,et al.  Modeling the Protonation States of the Catalytic Aspartates in β-Secretase , 2004 .

[32]  B. Platt,et al.  Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[33]  U. Ryde,et al.  Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. , 2006, Journal of Medicinal Chemistry.

[34]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[35]  Rajeev Prabhakar,et al.  Protonation States of the Catalytic Dyad of β-Secretase (BACE1) in the Presence of Chemically Diverse Inhibitors: A Molecular Docking Study , 2012, J. Chem. Inf. Model..

[36]  Roland L. Dunbrack.  Rotamer libraries in the 21st century. , 2002, Current opinion in structural biology.

[37]  Andrew Stamford,et al.  Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization. , 2010, Bioorganic & medicinal chemistry letters.

[38]  Tingjun Hou,et al.  Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking , 2011, J. Comput. Chem..

[39]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[40]  Haizhen A. Zhong,et al.  Modeling the protonation states of β-secretase binding pocket by molecular dynamics simulations and docking studies. , 2016, Journal of molecular graphics & modelling.

[41]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[42]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[43]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[44]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[45]  Yuan Cheng,et al.  From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.

[46]  M. Gilson,et al.  Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.

[47]  Lin Hong,et al.  Crystal Structure of Memapsin 2 (β-Secretase) in Complex with an Inhibitor OM00-3† , 2002 .

[48]  Ray Luo,et al.  Calculating protein–ligand binding affinities with MMPBSA: Method and error analysis , 2016, J. Comput. Chem..

[49]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[50]  Michael W. Mahoney,et al.  A five-site model for liquid water and the reproduction of the density anomaly by rigid, nonpolarizable potential functions , 2000 .

[51]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[52]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[53]  Wim F Vranken,et al.  ACPYPE - AnteChamber PYthon Parser interfacE , 2012, BMC Research Notes.

[54]  Shantenu Jha,et al.  Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors , 2014, Journal of chemical theory and computation.

[55]  Kenichiro Fujiwara,et al.  Conformational restriction approach to β-secretase (BACE1) inhibitors III: effective investigation of the binding mode by combinational use of X-ray analysis, isothermal titration calorimetry and theoretical calculations. , 2013, Bioorganic & medicinal chemistry.

[56]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[57]  Berk Hess,et al.  P-LINCS:  A Parallel Linear Constraint Solver for Molecular Simulation. , 2008, Journal of chemical theory and computation.

[58]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[59]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. , 2014, Physical chemistry chemical physics : PCCP.

[60]  György M. Keserü,et al.  Impact of Ligand Protonation on Virtual Screening against β-Secretase (BACE1) , 2007, J. Chem. Inf. Model..

[61]  Robert T. C. Brownlee,et al.  Effect of atomic charge, solvation, entropy, and ligand protonation state on MM‐PB(GB)SA binding energies of HIV protease , 2012, J. Comput. Chem..

[62]  William Greenlee,et al.  Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. , 2012, Journal of medicinal chemistry.

[63]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[64]  Erwin Laure,et al.  Solving Software Challenges for Exascale , 2014, Lecture Notes in Computer Science.

[65]  Jian Sun,et al.  Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. , 2006, Journal of medicinal chemistry.

[66]  Fredy Sussman,et al.  On a possible neutral charge state for the catalytic dyad in β-secretase when bound to hydroxyethylene transition state analogue inhibitors. , 2011, Journal of medicinal chemistry.

[67]  Martin Stahl,et al.  Tyramine fragment binding to BACE-1. , 2008, Bioorganic & medicinal chemistry letters.

[68]  Zhihai Liu,et al.  Comparative Assessment of Scoring Functions on an Updated Benchmark: 2. Evaluation Methods and General Results , 2014, J. Chem. Inf. Model..

[69]  Piotr Cieplak,et al.  Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. , 2002, Journal of medicinal chemistry.

[70]  Suresh Babu,et al.  Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.

[71]  Britt-Marie Swahn,et al.  Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease* , 2012, The Journal of Biological Chemistry.

[72]  Lin Hong,et al.  Design, Synthesis and X-ray Structure of Protein−Ligand Complexes: Important Insight into Selectivity of Memapsin 2 (β-Secretase) Inhibitors , 2006 .

[73]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[74]  Laura Pérez-Benito,et al.  Application of Free Energy Perturbation for the Design of BACE1 Inhibitors , 2016, J. Chem. Inf. Model..

[75]  M. Mansour,et al.  Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. , 2012, Journal of medicinal chemistry.

[76]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[77]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[78]  David D. Anderson,et al.  Structure-based design of highly selective β-secretase inhibitors: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. , 2012, Journal of medicinal chemistry.

[79]  Lynn A. Hyde,et al.  Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[80]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.

[81]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[82]  P Mark,et al.  298KでのTIP3P,SPC及びSPC/E水モデルの構造及び動力学 , 2001 .

[83]  Ying-zi Xu,et al.  Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.

[84]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[85]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[86]  Junya Qu,et al.  2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. , 2007, Journal of medicinal chemistry.